Prometheus Biosciences Inc, a biopharmaceutical company involved in the discovery, development, and commercialisation of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases, announced yesterday that it has named Thierry Dervieux, PharmD, PhD, DABCC as its new chief development officer, diagnostics, and medical laboratory director.
Dr Dervieux joins Prometheus Biosciences from Exagen Diagnostics where he served as chief scientific officer and medical director. Prior to joining Exagen, Dr Dervieux was vice president of research and development at Cypress Bioscience Inc and senior director of research and development with Proprius Pharmaceuticals Inc. Prior to that, he served as principal scientist and director of research and development at Prometheus Laboratories.
Mark McKenna, chief executive officer of Prometheus Biosciences, said, 'Thierry's deep expertise in the development of innovative diagnostic assays and drug monitoring tools will benefit us greatly as we continue to advance our novel precision medicine platform for GI and autoimmune conditions. We are thrilled to welcome Thierry and we look forward to his contributions as we take Prometheus to the next level.'
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval